Human cellular models to test lipid nanoparticle potency for mRNA

mRNA vaccine technologies came to the forefront of public health during the recent global pandemic and this technology also has great potential for other therapeutic approaches. These vaccine platforms require that the mRNA be encapsulated by fat molecules into structures called “lipid nanoparticles”, and the specific chemical formulations of the mRNA and fats determine the extent to which immune cells like monocytes are recruited to the intramuscular injection site and respond to the mRNA. To support advancement of new mRNA delivery formulations by biomanufacturers like industry partner BIOVECTRA, we will develop a platform to test mRNA lipid nanoparticle responses in human cells (fibroblasts, skeletal myotubes, and monocytes). This work will develop human models of vaccine potency that will be useful for testing new mRNA delivery formulations and will provide new approaches for testing immune responses to mRNAs and lipid nanoparticles, which will support development of safer and more effective therapeutics.

Faculty Supervisor:

Joel Ross

Student:

Partner:

BIOVECTRA Inc.

Discipline:

Life Sciences

Sector:

Biotechnology; Biomanufacturing; Health and Related Sciences & Technology

University:

University of Prince Edward Island

Program: